Work

Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-145569

Authors: Claire N. Harrison, John Mascarenhas, Pranav Abraham, Arianna Kee, Jose Alberto Nadal, Alexandrina Balanean, Ali McBride, Jonathan K. Kish, Djibril Liassou, Bruce A. Feinberg, Aaron T. Gerds

Institutions: Guy's and St Thomas' NHS Foundation Trust, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Bristol-Myers Squibb (United States), Cardinal Health (United States), Cleveland Clinic

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3214727871

Cites:

Cited by: 1

Related to: 10